Best Biotechnology Engineer Winnipeg Near Me

4worldlovers:
Leading the advancement of technologies and products that break up biofilms and destroy bacteria.


For over 20 years Kane Biotech’s R+D division has been developing new technologies and innovations leading to 80 patents and patents pending in biotechnology focusing primarily on biofilm.


Kane’s first Commercialization Vehicle formed in partnership with Animalcare Group, STEM Animal Health is a new animal health company dedicated to targeting biofilm-related ailments.


Biofilms are pervasive and represent the most prevalent bacterial mode of growth. The current wound care global market is expected to reach US $22 billion by 2022.

The strategic focus of the Kane Dermatology subsidiary is to develop and sell non-prescription consumables to end customers that address minor health ailments where biofilms contribute to the problem.


The study of biofilms has increased significantly in recent years due to the growing awareness of the pervasiveness and impact of biofilms on human and animal health, as well as natural and industrial systems.


The coactiv+ Wound Gel is a combination of Kane’s patented coactiv+ antibiofilm technology in a thermo-reversible gel that provides a moist environment best suited for wound healing.


Thermo-reversible gels, like coactiv+ Wound Gel, undergo a reversible transformation from liquid to gel with temperature. At room temperature, coactiv+ Wound Gel appears in a gel state, allowing for easy application onto wounds, including burns. Below 20 degrees Celsius (or in cold water), the gel transforms into a liquid state and can be easily removed from the skin.


Accessible for patients. The coactiv+ Wound Gel fits within reimbursement of US $19.88/oz with US $59.64/3oz for the monthly allowable - one of the ONLY wound gels within reimbursement.


Kane Biotech’s bluestem brand of pet oral care products are scientifically formulated with Kane’s patented coactiv+ technology to safely break down plaque and tartar biofilm and freshen breath.

STEM Pet Oral Care line is licensed globally for the Veterinary Market, through Dechra in North & South America, and Animalcare Group in the rest of the world.

STEM Animal Health received VOHC acceptance in 2022 as Kane’s coactiv+ technology was proven to significantly reduce accumulation of tartar.

A new scalp detoxifier and shampoo designed to break down biofilm.

Recent research has indicated that the persistence of biofilms may be linked with aggravating the symptoms associated with common scalp conditions, such as dandruff and seborrheic dermatitis.

Kane Dermatology launched a shampoo, shampoo bar and scalp detoxifier under the DermaKB brand as the first products in their new skin care line. The products are sold direct-to-consumer through Amazon and Kane’s online commerce site.

Kane had conducted an extensive consumer trial on DermaKB scalp care products with coactiv+ across North America with 4,500 participants suffering from a variety of common scalp conditions. Over 1,400 extensive questionnaires were completed, and of the participants who used both the DermaKB Detoxifier and Shampoo and rated their symptom as either extreme or severe before the trial, 82% identified an improvement in their symptom after using the products.

View our collection of videos on everything from business updates to industry webinars.

As part of our commitment to communicate more frequently with our investors in 2022, Kane Biotech Inc. introduces a new video blog series, with each video focused on one important topic that is driving our business forward.

From business update series to industry webinars, Kane Biotech has a number of past videos to watch at your leisure.

Click the images or titles below to read the full articles.

Raising Kane: The Secret to How Kane Biotech Got Its Name

Kane Biotech’s offices and laboratories are located in the University of Manitoba Smartpark Innovation Hub. It includes two independent analytical laboratories and three independent and well-equipped microbiology suites.

4worldlovers: Marsala Biotech Inc. is a Winnipeg, Canada, based new drug discovery and development company, concentrating on new treatments for cancer. The Company's lead technology, E10A, is an investigational gene therapy agent that utilizes an adenovirus vector to deliver the endostatin gene. E10A is being evaluated in patient populations to treat head and neck cancer, which accounts for 6% of all malignancies in the United States. A Phase II clinical trial of E10A in head and neck cancer patients (n=140) has been completed in China. E10A in combination with chemotherapy, significantly increased the Disease Control rate, and prolonged the median Time to Progression and median Progression Free Survival in these patients, as compared to chemotherapy alone.

Phase II/III clinical trials of E10A are expected to be initiated by 2017 in North America.

Download the executive summary to learn more about Marsala Biotech and E10A.

Cancer chemotherapy strives to cause a lethal cytotoxic event in the cancer cell that can arrest a tumour's progression. The attack is generally directed against metabolic sites essential to cell replication including, for example the availability of purines and pyrimidines that are the building blocks for DNA or RNA synthesis. Ideally these anticancer drugs should interfere only with cellular processes that are unique to malignant cells. Unfortunately most currently available anti-cancer drugs do not specifically recognize neoplastic cells, but rather affect all proliferating cells, both normal and abnormal.

Gene therapy is a technology which uses DNA as a pharmaceutical agent to supplement or alter genes within an individual as a therapy to treat disease. Marsala's product E10A uses the Endostatin gene to prevent angiogenesis (blood vessel growth), and shut off the nutrient supply to tumors, starving the tumors and leading to tumor shrinkage.

Marsala Biotech has an in-house drug discovery program to develop new chemical entities (NCEs) for the treatment/management of cancer.

Albert D. Friesen holds a Ph.D. in Protein Chemistry from the University of Manitoba. He has been instrumental in founding and the development of several health industry companies including ABI Biotechnology Canada's first profitable Biotech Company, (now Apotex Fermentation).

Dr. Friesen also led development of Canada's first biotech product, WinRho at Winnipeg Rh Institute Inc./Rh Pharmaceuticals (now Cangene) and is a founder of the Industrial Biotechnology Association of Canada (now BIOTECanada).